{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman&max-answer.dateOfAnswer=2015-12-15", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman&max-answer.dateOfAnswer=2015-12-15", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2015-12-08&_metadata=all&answer.answeringMemberPrinted=George+Freeman&max-answer.dateOfAnswer=2015-12-15", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman&max-answer.dateOfAnswer=2015-12-15", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman&max-answer.dateOfAnswer=2015-12-15", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman&max-answer.dateOfAnswer=2015-12-15", "items" : [{"_about" : "http://data.parliament.uk/resources/436264", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/436264/answer", "answerText" : {"_value" : "<br /><p>The Interim Report of Sir Hugh Taylor\u2019s Accelerated Access Review (AAR) is a deliberately high level document that indicates direction of travel; as such, government will be responding to the AAR\u2019s conclusions when its final recommendations are published early in the spring of 2016.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-15T16:30:10.483Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, whether he plan to respond to the Accelerated Access Review: Interim Report, published in October 2015; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "19241"}
    , {"_about" : "http://data.parliament.uk/resources/436265", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/436265/answer", "answerText" : {"_value" : "<p>NHS England and the National Institute for Health and Care Excellence are currently consulting jointly on draft proposals on the future direction of the Cancer Drugs Fund.<\/p><br /><p>The consultation was published on 19 November 2015 and is open until 11 February 2016. It states that it is looking to put in place a solution that ensures patients have routine access to a greater range of cancer drugs, including earlier access to innovative drugs, while ensuring that cost-effectiveness is maintained. Further information is available at:<\/p><p>www.engage.england.nhs.uk/consultation/cdf-consultation<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-15T16:22:51.767Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Leukaemia: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, if he will ensure that the new Cancer Drugs Fund will increase patient access to medicines for acute myeloid leukaemia.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "19240"}
    , {"_about" : "http://data.parliament.uk/resources/436266", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/436266/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of Orkambi (lumacaftor in combination with ivacaftor) for the treatment of cystic fibrosis in people who are homozygous for the F508del mutation. NICE\u2019s anticipated publication date for this guidance is July 2016. Further information is available at:<\/p><br /><p>www.nice.org.uk/guidance/indevelopment/gid-tag530<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-15T16:20:22.32Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, when he expects Orkambi to be appraised by NICE.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
      }
      , "tablingMemberConstituency" : {"_value" : "York Outer"}
      , "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
      ], "uin" : "19234"}
    , {"_about" : "http://data.parliament.uk/resources/436267", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/436267/answer", "answerText" : {"_value" : "<p>We receive representations about the National Institute for Health and Care Excellence\u2019s (NICE) technology appraisal programme from hon. Members, members of the public, clinicians and the pharmaceutical industry.<\/p><br /><p>NICE is the independent body that provides guidance on the prevention and treatment of ill health and the promotion of good health and social care and is responsible for its own processes and methodology.<\/p><br /><p>NICE regularly reviews these and its internationally renowned technology appraisal programme has evolved constantly to meet new challenges. NICE has demonstrated its ability to adapt to changes in the health and care environment, and we expect it will continue to evolve in the future, in particular through the recommendations of the Accelerated Access Review which NICE is centrally involved in.<\/p><br /><p>Further guidance on NICE\u2019s processes of technology appraisal is available at:<\/p><br /><p>www.nice.org.uk/article/pmg19/chapter/Foreword<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-15T16:28:02.747Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what representations he has received on reforming of NICE's procedure for appraisal of medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
      }
      , "tablingMemberConstituency" : {"_value" : "York Outer"}
      , "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
      ], "uin" : "19235"}
    , {"_about" : "http://data.parliament.uk/resources/436268", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/436268/answer", "answerText" : {"_value" : "<p>NHS England is responsible for commissioning specialised neurological services, which includes services for patients with neuromuscular disorders. NHS England has published a service specification for neurological care, which sets out what providers must have in place to offer evidence-based, safe and effective services. The specification can be found at the following link:<\/p><p>www.england.nhs.uk/wp-content/uploads/2013/06/d04-neurosci-spec-neuro.pdf<\/p><br /><p>Specialised neuromuscular care may include referral to local physiotherapy, hydrotherapy or rehabilitation if appropriate, however the commissioning of hydrotherapy services is a matter for local clinical commissioning groups. There are no plans to conduct a national review of hydrotherapy provision.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "18884"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-10T17:17:25.013Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Hydrotherapy"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, if he will conduct a national review of hydrotherapy provision.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/151", "label" : {"_value" : "Biography information for Tom Brake"}
      }
      , "tablingMemberConstituency" : {"_value" : "Carshalton and Wallington"}
      , "tablingMemberPrinted" : [{"_value" : "Tom Brake"}
      ], "uin" : "19246"}
    , {"_about" : "http://data.parliament.uk/resources/435872", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/435872/answer", "answerText" : {"_value" : "<p>NHS England is responsible for commissioning specialised neurological services, which includes services for patients with neuromuscular disorders. NHS England has published a service specification for neurological care, which sets out what providers must have in place to offer evidence-based, safe and effective services. The specification can be found at the following link:<\/p><p>www.england.nhs.uk/wp-content/uploads/2013/06/d04-neurosci-spec-neuro.pdf<\/p><br /><p>Specialised neuromuscular care may include referral to local physiotherapy, hydrotherapy or rehabilitation if appropriate, however the commissioning of hydrotherapy services is a matter for local clinical commissioning groups. There are no plans to conduct a national review of hydrotherapy provision.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "19246"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-10T17:17:24.933Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Muscular Dystrophy: Hydrotherapy"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, if he will take steps to improve access for patients with muscular dystrophy to hydrotherapy services.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/18", "label" : {"_value" : "Biography information for Dame Cheryl Gillan"}
      }
      , "tablingMemberConstituency" : {"_value" : "Chesham and Amersham"}
      , "tablingMemberPrinted" : [{"_value" : "Mrs Cheryl Gillan"}
      ], "uin" : "18884"}
    , {"_about" : "http://data.parliament.uk/resources/435878", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/435878/answer", "answerText" : {"_value" : "<p>NHS England would expect commissioners to take account of this guidance when commissioning services.<\/p><br /><p>Any transfer of budget from NHS England to devolved areas will be on the basis of existing contractual activity.<\/p><br /><p>Before the transfer of services, NHS England will complete a data capture exercise, working with providers through the specialised commissioning hubs, to collect the current activity level. This will provide the basis for the transfer of the budget. Governance sign off will then be agreed at NHS England Board level.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-15T12:38:22.057Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Obesity: Surgery"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what account will be taken of NICE's clinical guidelines on levels of patient access in setting the budgets devolved by NHS England to clinical commissioning groups for obesity surgery from April 2016.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"}
      }
      , "tablingMemberConstituency" : {"_value" : "Totnes"}
      , "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"}
      ], "uin" : "18841"}
    , {"_about" : "http://data.parliament.uk/resources/435879", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/435879/answer", "answerText" : {"_value" : "<p>The template is in development and the draft will be shared in January 2016.<\/p><br />"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-15T12:51:34.827Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Obesity: Surgery"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, when NHS England's Clinical Reference Group for Severe and Complex Obesity will publish its proposed template for clinical commissioning groups on access to obesity surgery pathways and follow-up treatment.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"}
      }
      , "tablingMemberConstituency" : {"_value" : "Totnes"}
      , "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"}
      ], "uin" : "18842"}
    , {"_about" : "http://data.parliament.uk/resources/435881", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/435881/answer", "answerText" : {"_value" : "<p>We do not expect obesity outcomes to be affected, as the change will primarily be in regard to commissioning responsibilities. However, we believe the transfer should support better integration between Tier 3 and Tier 4 services (which include obesity services) which in turn should improve patient pathways.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-15T12:56:11.067Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Obesity: Surgery"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the potential effect on patient outcomes of the planned transfer of obesity surgery commissioning responsibilities to clinical commissioning groups from April 2016.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"}
      }
      , "tablingMemberConstituency" : {"_value" : "Totnes"}
      , "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"}
      ], "uin" : "18864"}
    , {"_about" : "http://data.parliament.uk/resources/435890", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/435890/answer", "answerText" : {"_value" : "<p>The conditions/therapy areas selected for the New Medicine Service (NMS) are those where community pharmacies are best able to demonstrate the value of the service and could provide the greatest benefit to patients. The conditions/therapy areas are currently asthma and chronic obstructive pulmonary disease, type 2 diabetes, antiplatelet/anticoagulant therapy and hypertension.<\/p><br /><p>As the commissioners of National Health Service pharmaceutical services it is for NHS England to consider, in light of the best available evidence, whether to negotiate changes to the NMS including whether the NMS should be offered to mental health patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-10T13:27:59.86Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mental Health Services: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, for what reasons the New Medicine Service is not available to mental health patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
      , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
      ], "uin" : "19041"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman&max-answer.dateOfAnswer=2015-12-15", "page" : 0, "startIndex" : 1, "totalResults" : 1110, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}